Key facts
- Biolog’s last known valuation is $33.1M (Feb 2025).
- It has raised $33.6M; the latest was Later Stage VC ($16.1M) in Feb 2025.
- Notable investors include BroadOak Capital Partners, JPMorgan Life Sciences Private Capital, National Cancer Institute, National Institute Of Allergy and Infectious Diseases, National Institute of General Medical Sciences — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Biolog
- ·The full record, as it builds
Funding rounds
No funding rounds for Biolog are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Biolog
Developer of cell analysis tools designed to identify cell phenotypes for early-stage detection of diseases. The company offers a range of cellular analysis instruments, identification microplates, metabolic and community analysis panels, laboratory testing services, and specialized reagents and software, enabling quality control teams to perform detailed biological characterization and make informed decisions based on empirical data.
- Sector
- Healthcare
- HQ
- Hayward, CA, United States
- Founded
- 1984
- Employees
- 110
- Website
- biolog.com/
- Ownership
- Privately Held (backing)
Biolog doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biolog shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biolog in its N-PORT filings yet. We sweep new filings monthly.